EMBER-3 Trial: Imlunestrant Plus Abemaciclib Improves Survival in Advanced Breast Cancer
Komal Jhaveri, MD, FACP, breast oncologist and early drug development specialist at Memorial Sloan Kettering Cancer Center, presents findings from the EMBER-3 trial evaluating imlunestrant for patients with advanced breast cancer.
Lilly Reports Positive Phase 3 EMBER-3 Study Data In Advanced Breast Cancer
In the EMBER-3 study, estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer patients were randomized to receive imlunestrant alone, standard of care endocrine therapy, or a combination of imlunestrant with Lilly's breast cancer drug Verzenio.
With new data, Lilly sets pace for next wave of breast cancer drugs
While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace fulvestrant.
Eli Lilly's Investigational Cancer Drug Cuts Risk Of Death By 38% In Breast Cancer Patients
Eli Lilly And Co (NYSE:LLY) announced results from the Phase 3 EMBER-3 study of imlunestrant for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 negative advanced breast cancer,
Lilly’s Phase III SERD breast cancer study has success in certain patients
The Phase III study saw the drug able to cut the risk of disease progression or death by 38% with imlunestrant alone, and down so far as 43% when combined with Verzenio.
Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study
Eli Lilly LLY announced results from the phase III EMBER-3 study, which showed that treatment with its orally administered investigational drug imlunestrant significantly reduced the risk of disease progression or death in certain patients with advanced breast cancer (ABC).
Lilly reports positive Phase 3 breast cancer data for imlunestrant
Imlunestrant is being evaluated in patients with ER+/HER2- advanced breast cancer, whose disease progressed on a prior aromatase inhibitor, with or without a CDK4/6 inhibitor. Ove
FierceBiotech1d
SABCS: Eli Lilly's oral SERD Ember counts on Verzenio to broaden its glow
It looks like Eli Lilly’s oral selective estrogen receptor degrader (SERD) imlunestrant may need some extra help to reach a ...
Eli Lilly announces results from EMBER-3 study of imlunestrant
Eli Lilly (LLY) announced results from the Phase 3 EMBER-3 study of imlunestrant, an investigational, oral selective estrogen receptor ...
healthandpharma12h
New Oral SERD Imlunestrant Shows Promising Results Alone and with Verzenio in ER+, HER2- Breast Cancer
Imlunestrant, an oral SERD, significantly prolonged progression-free survival in patients with advanced ER+, HER2- breast ...
mskcc.org2d
Imlunestrant: A Promising Oral Therapy Option for Patients with ER+/HER2- Advanced Breast Cancer
A groundbreaking international study has found that imlunestrant plus abemaciclib significantly improved progression-free survival (PFS) versus imlunestrant monotherapy in patients with estrogen ...
Next-generation treatment protects against progression in some patients with advanced breast cancer
Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free ...
MedPage Today1d
Oral SERD Impresses in Advanced Breast Cancer With ESR1 Mutations
Interim overall survival (OS) analyses at 31% maturity in patients with ESR1 mutations, and 23% maturity among all patients, ...